Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs)

被引：2
|
作者：
Gutierrez, M. E. [1 ]
Giaccone, G. [2 ]
Liu, S. V. [2 ]
Rajan, A. [3 ]
Guha, U. [3 ]
Halfdanarson, T. R. [4 ]
Curtis, K. K. [5 ]
Kunz, P. L. [6 ]
Gabrail, N. [7 ]
Hinson, J. M. [8 ]
Orlemans, E. O. [9 ]
机构：
[1] John Theurer Canc Ctr, Hematol & Oncol, Hackensack, NJ USA
[2] Georgetown Univ, Lombardi Canc Ctr, Hematol & Oncol, Washington, DC USA
[3] NCI, Thorac & Gastrointestinal Oncol, Ctr Canc Res, Bethesda, MD 20892 USA
[4] Mayo Clin, Med, Rochester, MN USA
[5] Mayo Clin, Internal Med, Scottsdale, AZ USA
[6] Stanford Univ, Sch Med, Med Oncol, Palo Alto, CA 94304 USA
[7] Gabrail Canc Ctr, Hematol, Canton, OH USA
[8] Unicorn Pharma Consulting, Clin Res, Nashville, TN USA
[9] Esanex Inc, Clin Res, Indianapolis, IN USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw369.8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
423PD
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC
    Bauer, Todd M.
    Besse, Benjamin
    Martinez-Marti, Alex
    Trigo, Jose Manuel
    Moreno, Victor
    Garrido, Pilar
    Ferron-Brady, Geraldine
    Wu, Yuehui
    Park, Jennifer
    Collingwood, Therese
    Kruger, Ryan G.
    Mohammad, Helai P.
    Ballas, Marc S.
    Dhar, Arindam
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : 1828 - 1838
  • [42] Open-label, phase IIIb, multicenter, expanded access study of everolimus in patients with advanced neuroendocrine tumors (NET)
    Bechter, Oliver Edgar
    Unger, Nicole
    Borbath, Ivan
    Ricci, Sergio
    Hwang, Tsann-Long
    Park, Young Suk
    Tomasek, Jiri
    Raef, Hussein
    Laohavinij, Sudsawat
    JeanLouis, Lisa
    Panneerselvam, Ashok
    Saletan, Stephen
    Stergiopoulos, Sotirios G.
    Pavel, Marianne E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers
    Diab, Adi
    Hamid, Omid
    Thompson, John A.
    Ros, Willeke
    Eskens, Ferry A. L. M.
    Doi, Toshihiko
    Hu-Lieskovan, Siwen
    Klempner, Samuel J.
    Ganguly, Bishu
    Fleener, Catherine
    Wang, Xiao
    Joh, Tenshang
    Liao, Ken
    Salek-Ardakani, Shahram
    Taylor, Carrie Turich
    Chou, Jeffrey
    El-Khoueiry, Anthony B.
    CLINICAL CANCER RESEARCH, 2022, 28 (01) : 71 - 83
  • [44] A phase I open-label, dose-escalation study of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer
    Littman, Susan Joy
    Monti, Daniel
    Newberg, Andrew
    Bazzan, Anthony
    Pillai, Madhavan V.
    Lewis, Nancy
    Yeo, Charles
    Levine, Mark
    Mitchell, Edith P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [45] Phase I dose-escalation study of aflibercept plus docetaxel in nasopharyngeal carcinoma and other solid tumors
    Huang, Yan
    Zou, Ben-Yan
    Zhao, Li-Ping
    Zhao, Hong-Yun
    Zhao, Yuan-Yuan
    Xue, Cong
    Zhang, Jian-Wei
    Xu, Fei
    Chen, Li-Kun
    Liu, Jun-Ling
    Hu, Zhi-Huang
    Wu, Xuan
    Zhang, Jing
    Ma, Yu-Xiang
    Wei, Chen-Lu
    Ma, Ying
    Zhang, Li
    FUTURE ONCOLOGY, 2014, 10 (16) : 2579 - 2591
  • [46] A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY AND TOLERABILITY STUDY OF NC762 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
    Myint, Han
    Shah, Satish
    Gutierrez, Martin
    Zsiros, Emese
    Nelson, Megan
    Zeidan, Stephanie
    Myrthil, Nadia
    Morawski, Aaron
    Barbu, Alina
    Shaik, Jahangheer
    Zhou, Chelsea
    Kanellopoulou, Chrysi
    Copeland, Ron
    Cusumano, Zachary
    Flies, Dallas
    Langermann, Solomon
    Lorusso, Patricia
    Odunsi, Kunle
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A781 - A781
  • [47] A phase Ib, open-label, dose-escalation study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors.
    Eskens, F.
    Oldenhuis, C. N.
    Bhargava, P.
    Loos, W.
    Esteves, B.
    van Doorn, L.
    Cotreau, M. M.
    Dhillon, R.
    Gietema, J. A.
    De Vries, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [48] Open-Label, Dose-Escalation, Phase 1 Study of Safety and Single and Multiple-Dose Pharmacokinetics of Dichlorphenamide in Healthy Volunteers
    Cohen, Fredric
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (01): : 87 - 94
  • [49] An Open-label Phase 1 Dose-escalation Clinical Trial of a Single Intravenous Administration of Gemcitabine in Dogs with Advanced Solid Tumors
    Marconato, L.
    Finotello, R.
    Bonfanti, U.
    Dacasto, M.
    Beatrice, L.
    Pizzoni, S.
    Leone, V. F.
    Balestra, G.
    Furlanello, T.
    Bley, C. Rohrer
    Aresu, L.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2015, 29 (02): : 620 - 625
  • [50] Trial in progress: A phase I/II, open-label, dose-escalation, safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors.
    Gutierrez, Martin
    Hamid, Omid
    Shum, Elaine
    Wise, David R.
    Balar, Arjun Vasant
    Weber, Jeffrey S.
    LoRusso, Patricia
    Shafi, Saba
    Rimm, David L.
    Tolcher, Anthony W.
    Basudhar, Debashree
    Dujka, Melanie Elizabeth
    Heller, Kevin N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345